Loading...
Acalabrutinib monotherapy in patients with chronic lymphocytic leukemia who are intolerant to ibrutinib
The Bruton tyrosine kinase (BTK) inhibitor ibrutinib improves patient outcomes in chronic lymphocytic leukemia (CLL); however, some patients experience adverse events (AEs) leading to discontinuation. Acalabrutinib is a potent, covalent BTK inhibitor with greater selectivity than ibrutinib. We evalu...
Saved in:
| Published in: | Blood Adv |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , , , |
| Format: | Artigo |
| Language: | Inglês |
| Published: |
American Society of Hematology
2019
|
| Subjects: | |
| Online Access: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6517672/ https://ncbi.nlm.nih.gov/pubmed/31088809 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2018030007 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|